Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$148.98 USD
-3.69 (-2.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.88 -0.10 (-0.07%) 7:06 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 381 - 400 ( 667 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Glimpse of Launch Progress Coming in January as Sarepta Reports 3Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thinking About the US Launch of Exondys 51; Reiterate OUTPERFORM and Raise PT to $72
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Good News Keeps Coming - Interference Case Means Sarepta Should be Able to Launch Unencumbered in the US; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Finally Gets to YES on Eteplirsen; Reiterate OUTPERFORM and Raise PT to $66
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Reports 2Q16 Earnings as We Wait on an Accelerated Approval Decision; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As We Await an FDA Decision on Eteplirsen, Sarepta Looks Forward with Changes to Exon 45/53 Trial Design; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM; FDA Comes Up with Option "C"; PT to $36
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H